Beyond Automotive: Pharma and Medtech as Industrial Lighthouses

The upcoming USMCA review scheduled for July 2026, combined with tariff measures introduced during the Trump administration and later reinforced through sector-specific trade enforcement, has increased uncertainty around Mexico’s flagship automotive industry. Mexico remains the leading supplier of auto parts to the United States, yet recent data shows a contraction in automotive exports, a slowdown in new investment, and growing pressure on margins as rules of origin, labor provisions, and sectoral tariffs tighten.

At the same time, nearshoring dynamics and a renewed industrial policy are reshaping Mexico’s economic strategy[1]. President Claudia Sheinbaum’s Plan México[2] aims to raise investment to 25% of GDP by 2026 and create 1.5 million well-paid jobs. The plan explicitly promotes higher-value manufacturing, stronger local supply chains, and the development of Development Poles (PODECOBIS[3]): industrial zones supported by infrastructure, financing, and fiscal incentives.

With automotive exports and foreign direct investment under pressure, Mexico needs to complement, not replace, its automotive strength with new industrial lighthouses. The pharmaceutical and medical device industries offer solid domestic capabilities, growing export relevance, and strategic value for supply chain resilience. Together, they position Mexico as a credible gateway to the North American healthcare market.

Automotive at a Crossroads: A Strategic Warning

The automotive sector remains a cornerstone of Mexico’s industrial base, representing roughly a quarter of manufacturing exports and employing hundreds of thousands of skilled workers. However, recent trends signal a turning point that must be considered carefully in the context of the USMCA renegotiation.

In 2025, non-automotive manufacturing exports grew at double-digit rates, while automotive exports contracted, partly due to stricter enforcement of sector-specific tariffs and rules of origin[4]. Automotive FDI has increasingly shifted toward reinvestment rather than new greenfield projects, reflecting caution among global OEMs and suppliers. At the same time, the global transition toward electromobility is reorganizing value chains, pushing competition upstream into batteries, electronics, software, and advanced materials — areas where Mexico still has gaps.

This is not a pessimistic outlook, but a strategic alert. Mexico must simultaneously defend and modernize its automotive base while accelerating the development of other sectors where it already has scale, talent, and market access.

Pharmaceuticals: From Domestic Market to North American Supply Chains

Mexico’s pharmaceutical industry has quietly expanded and diversified over the past decade. According to trade and industrial data[5], Mexico exported over 50 pharmaceutical products in 2023 that it did not manufacture 10 years ago, reflecting a gradual move up the value chain. In the same year, Mexico exported 165 pharmaceutical and API products classified as critical by US authorities, with exports exceeding US$2.5 billion.

While Mexico’s share of total US pharmaceutical imports remains modest (around 1.5%), the strategic relevance is significant. The United States continues to face persistent drug shortages, particularly in generics and essential hospital medicines, highlighting the risks of over-concentration in Asian suppliers. Mexico offers a geographically close, cost-competitive, and USMCA-aligned alternative.

Foreign direct investment also reflects this momentum. Between January and September 2024, pharmaceutical manufacturing attracted US$784 million in FDI, with cumulative investment exceeding US$15 billion since 1999. Clusters in Mexico City, State of Mexico, Jalisco[6], and emerging regions such as Chihuahua and Baja California provide an industrial base that can be scaled further.

To unlock its full potential, the sector must overcome barriers related to regulatory timelines, API production capacity, and clinical research integration. However, the direction is clear: Pharmaceuticals can evolve from a domestic-oriented industry into a strategic component of North American health security.

Medical Devices: A Proven Export Champion Ready to Scale

Medical devices represent one of Mexico’s most mature and export-oriented high-tech manufacturing sectors. Mexico is currently the largest supplier of medical devices to the United States and among the top global exporters worldwide[7]. Annual exports exceed US$12 billion, with strong positions in consumables, diagnostic equipment, surgical instruments, and hospital supplies.

The sector benefits from deep integration with US and Canadian value chains, particularly in Baja California, Chihuahua, Nuevo Leon, and Jalisco. Regulatory alignment between COFEPRIS and the US FDA in this field has improved market access and reduced friction compared to other regulated industries.

Beyond manufacturing, Mexico is increasingly relevant for design, validation, and clinical testing, supported by a growing network of hospitals, research centers, and specialized suppliers. This positions medical devices as a natural bridge between manufacturing excellence and healthcare innovation.

Why the Current Context Favors These Two Sectors

Several structural factors are already aligning in favor of pharmaceuticals and medical devices:

• Plan México and PODECOBIS are explicitly prioritizing health-related manufacturing, including APIs, medical supplies, and advanced devices.
• Nearshoring pressures are pushing US and Canadian companies to diversify suppliers closer to home, especially in regulated and critical sectors.
• Regulatory modernization at COFEPRIS, while still uneven, has shown concrete progress in medical devices and is under pressure to improve further in pharmaceuticals.
• Talent and cost advantages allow Mexico to compete not only on manufacturing, but increasingly on engineering, quality systems, and clinical operations.

Together, these elements create a foundation for Mexico to position itself alongside Europe and Asia as a strategic location for healthcare manufacturing serving North America.

What Still Needs to Be Strengthened

To consolidate the pharmaceutical and medical device sectors as true industrial lighthouses for Mexico, several gaps must be analyzed and addressed in a structured and collective manner.

• Defining a shared national vision for healthcare manufacturing. Fragmentation among government, industry, and academia limits impact; a unified, long-term strategy aligned with Plan México and the USMCA would provide clarity, credibility, and direction for international partners.
• Accelerating regulatory approvals without lowering standards. Faster, more predictable approval timelines are critical to compete for nearshoring investment, but this must be achieved through process efficiency and international regulatory reliance, not by weakening quality or safety requirements.
• Strengthening clinical research infrastructure and hospital participation. Mexico’s large patient base and hospital network are strategic assets, yet limited integration with global clinical trials reduces value capture; aligning hospitals, regulators, and industry would anchor higher-value R&D activities locally[8].
• Scaling API and high-value component production. Dependence on imported APIs and critical inputs exposes structural vulnerability; targeted investment in domestic production would enhance supply-chain resilience and position Mexico as a more complete North American manufacturing platform.

These are not structural weaknesses, but policy and coordination challenges that can be addressed within the USMCA framework and Plan México.

Mexico does not need to move away from automotive manufacturing to secure its industrial future. But it does need to broaden its industrial leadership. Pharmaceuticals and medical devices already generate exports, investment, and skilled employment at scale. With the right regulatory, innovation, and coordination efforts, they can become the next lighthouses supporting Mexico’s role as a trusted industrial partner for North America.

Sources:

[1] Mexico Nearshoring Boom: Record $41B FDI in 2025 Fuels Manufacturing Expansion

[2] https://www.planmexico.gob.mx/

[3] https://www.proyectosmexico.gob.mx/proyecto_inversion/polos-de-desarrollo-economico-para-el-bienestar/?language=en

[4] https://www.prodensa.com/insights/blog/the-export-boom-revolutionizing-manufacturing-in-mexico

[5] https://www.wilsoncenter.org/article/trends-and-opportunities-mexico-us-pharma-trade

[6] Pharmaceutical and Medicine Manufacturing: Wages, production, investment, opportunities and complexity | Data México

[7] https://oec.world/en/profile/hs/medical-instruments?tab=exporter

[8] https://pharmaboardroom.com/articles/mexico-towards-a-clinical-trials-powerhouse/